M-BACOD                                           lymphoma(96,97)
 _________________________________________________________________
  methotrexate.... 200 mg/sqm IV on days 8 and 15.
  leucovorin...... 10 mg/sqm orally every 6 h times 8 beginning 24 
                   hours after methotrexate.
  bleomycin....... 4 mg/sqm IV day 1.
  adriamycin...... 45 mg/sqm IV day 1.
  cytoxan......... 600 mg/sqm IV day 1.
  vincristine..... 1.0 mg/sqm IV day 1.
  dexamethasone... 6.0 mg/sqm/day orally from day 1 to day 5.
  FREQUENCY....... Repeat cycle every 21 days for 10 cycles. 

   96. Skarin AT, Canellos G, Rosenthal D, et.al. Moderate dose 
       methotrexate (m) combined with bleomycin (B), adriamycin 
       (A), cyclophosphamide (C), Oncovin (O), and dexamethasone 
       (D), m-BACOD, in advanced diffuse histiocytic lymphoma. Proc 
       Soc Clin Onocl 2:220, 1983.

  reference...
    Shipp MA.  Harrington DP.  Klatt MM.  Jochelson MS.  Pinkus 
    GS.  Marshall JL. Rosenthal DS.  Skarin AT.  Canellos GP. 
    Identification of major prognostic subgroups of patients with 
    large-cell lymphoma treated with m-BACOD or M-BACOD. Annals of 
    Internal Medicine.  104(6):757-65, 1986 Jun. 
  abstract...
    One hundred twenty-one patients with diffuse large-cell 
    lymphoma treated with m- or M-BACOD (methotrexate, bleomycin, 
    doxorubicin, cyclophosphamide, vincristine, and dexamethasone) 
    were evaluated for pretreatment characteristics predictive for 
    response and survival. Two characteristics, poor performance 
    status and massive bulky disease, were negatively associated 
    with response rate in a multivariate analysis. These two 
    characteristics were also negatively associated with survival 
    in multivariate analysis, as was another factor, an increased 
    number of extranodal sites of disease. These three 
    pretreatment characteristics were used to construct a model 
    containing 12 categories of patients at increasing risk for 
    relapse and shortened survival. These categories divided 
    naturally into three broad groups of patients with respective 
    5-year survival rates of 68%, 55%, and 24%.